RTP Mobile Logo
Meet The Professor: Non-Small Cell Lung Cancer with an Actionable Target Beyond EGFR — Part 3 of a 4-Part Series (Webinar Video Proceedings)
Released July 2022

Featuring perspectives from Dr Melissa Johnson. Published July 12, 2022. (Webinar Video Proceedings)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of lung cancer.

    LEARNING OBJECTIVES

    • Recognize the spectrum of oncogenic alterations beyond those associated with EGFR identifiable in patients with non-small cell lung cancer (NSCLC), and determine how these may predict potential response to novel targeted therapies.
    • Appraise the efficacy and safety of approved and investigational ALK inhibitors, and determine how these agents can be integrated into the protocol and nonresearch care of patients with NSCLC with ALK rearrangements.
    • Consider the mechanism of action of entrectinib, available data and the FDA approval of that agent for patients with NSCLC with ROS1 alterations, and discern how it can be appropriately and safely integrated into routine clinical care.
    • Assess available clinical trial findings supporting the FDA approvals of capmatinib and tepotinib for metastatic NSCLC with MET exon 14 skipping mutations, and identify patients who might benefit from these agents.
    • Recall the FDA approvals of selpercatinib and pralsetinib for patients with RET-driven metastatic NSCLC, and evaluate how these agents should be appropriately and safely integrated into clinical practice.
    • Recollect other oncogenic pathways (ie, HER2, KRAS) mediating the pathogenesis of tumors in unique patient subsets, and recall published and emerging data with commercially available and experimental agents exploiting these targets.
    • Recognize common and rare side effects associated with novel targeted agents employed in the treatment of NSCLC, and use this information to develop supportive management plans for patients.
    • Assess ongoing clinical research evaluating novel agents and treatment strategies for patients with NSCLC harboring actionable mutations beyond EGFR, and offer counsel about the potential benefits of trial participation.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    Audio Program: Research To Practice designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Video Program: Research To Practice designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    Successful completion of these CME activities, which includes participation in the evaluation components and short post-tests, enables the participant to earn up to 1.75 (audio) and 1.25 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, these programs have been specifically designed for the following ABIM specialty: medical oncology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    HOW TO USE THIS CME ACTIVITY
    Audio Program: This CME activity consists of an audio component. To receive credit, the participant should review the CME information, listen to the MP3s, review the downloadable slide set, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/MTPTargetedLung/Part3/CME. The corresponding video program is available as an alternative at ResearchToPractice.com/MTPTargetedLung/Part3/Video.

    Video Program: This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/MTPTargetedLung/Part3/Video/CME. The corresponding audio program is available as an alternative at ResearchToPractice.com/MTPTargetedLung/Part3.

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

    Melissa Johnson, MD
    Director, Lung Cancer Research Program
    Associate Director of Drug Development for the Drug Development Unit in Nashville
    Sarah Cannon Research Institute
    Nashville, Tennessee

    Consulting Agreements (All to Institution): AbbVie Inc, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Axelia Oncology, Black Diamond Therapeutics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Calithera Biosciences, Checkpoint Therapeutics Inc, CytomX Therapeutics, Daiichi Sankyo Inc, EcoR1 Capital LLC, Editas Medicine, Eisai Inc, EMD Serono Inc, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gritstone Oncology, IDEAYA Biosciences, iTeos Therapeutics, Janssen Biotech Inc, Lilly, Merck, Mirati Therapeutics Inc, Oncorus, Regeneron Pharmaceuticals Inc, Ribon Therapeutics, Sanofi Genzyme, Turning Point Therapeutics Inc, WindMIL Therapeutics; Contracted Research (All to Institution): AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptimmune, Amgen Inc, Apexigen, Arcus Biosciences, Array BioPharma Inc, a subsidiary of Pfizer Inc, AstraZeneca Pharmaceuticals LP, Atreca, BeiGene Ltd, BerGenBio ASA, BioAtla, Boehringer Ingelheim Pharmaceuticals Inc, Calithera Biosciences, Checkpoint Therapeutics Inc, Corvus Pharmaceuticals, Curis Inc, CytomX Therapeutics, Daiichi Sankyo Inc, Dracen Pharmaceuticals, Dynavax, Elicio Therapeutics, EMD Serono Inc, Erasca, Genentech, a member of the Roche Group, Genmab, Genocea, GlaxoSmithKline, Gritstone Oncology, Guardant Health, Harpoon Therapeutics, Helsinn Healthcare SA, Hengrui Therapeutics Inc, Hutchison MediPharma, IDEAYA Biosciences, IGM Biosciences Inc, Immunocore, Incyte Corporation, Janssen Biotech Inc, Jounce Therapeutics, Kadmon, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Lycera, Memorial Sloan Kettering Cancer Center, Merck, Mirati Therapeutics Inc, NeoImmuneTech, Neovia Oncology, Novartis, Numab, Nuvalent, OncoMed Pharmaceuticals Inc, Pfizer Inc, PMV Pharma, Rain Therapeutics, Rascal Therapeutics, Regeneron Pharmaceuticals Inc, Relay Therapeutics, Revolution Medicines, Ribon Therapeutics, Rubius Therapeutics, Sanofi Genzyme, Seven and Eight Biopharmaceuticals Inc, Shattuck Labs, Silicon Therapeutics, Stemcentrx, Takeda Pharmaceuticals USA Inc, Tarveda Therapeutics, TCR2 Therapeutics, Tempest Therapeutics, Tizona Therapeutics Inc, Tmunity Therapeutics Inc, Turning Point Therapeutics Inc, University of Michigan, Vyriad, WindMIL Therapeutics, Y-mAbs Therapeutics Inc.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, the parent company of GHI, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    These activities are supported by educational grants from Amgen Inc, AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Elevation Oncology Inc, Genentech, a member of the Roche Group, Novartis, and Turning Point Therapeutics Inc.

    Release date: July 2022
    Expiration date: July 2023

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Watch video
(WIFI is recommended for best performance):